Australia markets open in 5 hours 33 minutes

iBio, Inc. (IBIO)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.3050+0.0050 (+0.22%)
As of 02:21PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.3000
Open2.3700
Bid2.3000 x 1100
Ask2.3100 x 1100
Day's range2.3001 - 2.3900
52-week range1.0200 - 16.0000
Volume49,338
Avg. volume3,887,917
Market cap19.878M
Beta (5Y monthly)-3.35
PE ratio (TTM)N/A
EPS (TTM)-7.2300
Earnings date14 May 2024 - 18 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    iBio Closes Sale of Manufacturing Facility in Texas

    – The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following

  • GlobeNewswire

    iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

    Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update. “In our third fiscal quarter, we continued to advance toward our goal

  • GlobeNewswire

    iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

    – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – B